comparemela.com

Latest Breaking News On - Mannkind corp - Page 6 : comparemela.com

MannKind (NASDAQ:MNKD) Reaches New 1-Year High Following Analyst Upgrade

Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) hit a new 52-week high on Wednesday after Cantor Fitzgerald raised their price target on the stock from $6.50 to $7.50. Cantor Fitzgerald currently has an overweight rating on the stock. MannKind traded as high as $5.75 and last traded at $5.64, with a volume of […]

MannKind: Q2 Earnings Snapshot

DANBURY, Conn. (AP) — DANBURY, Conn. (AP) — MannKind Corp. (MNKD) on Monday reported a loss of $5.3 million in its second quarter.

Comparing MannKind (NASDAQ:MNKD) & Greenwich LifeSciences (NASDAQ:GLSI)

MannKind (NASDAQ:MNKD – Get Free Report) and Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Valuation & Earnings This table compares MannKind and […]

Insulin pump market to grow by USD 5,465 96 million from 2022 to 2027|The rising global burden of diabetes drives growth

/PRNewswire/ The insulin pump market size is expected to increase by USD 5,465.96 million from 2022 to 2027, registering a CAGR of 16.25%, according to the.

Raymond James & Associates Raises Holdings in MannKind Co (NASDAQ:MNKD)

Raymond James & Associates grew its holdings in MannKind Co. (NASDAQ:MNKD – Get Rating) by 80.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 619,267 shares of the biopharmaceutical company’s stock after acquiring an additional 276,588 shares during the period. Raymond James & Associates’ holdings in MannKind were worth $3,264,000 at the end […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.